Introduction
The
current US HIV epidemic calls for urgent attention in addressing rates
of HIV transmission among men and transgender women who have sex with
men (MTW) [1].
Of great concern, are the race-related disparities in HIV transmission,
in particular, the exceedingly high rates of HIV infection among
Black/African–American MTW (BMTW) compared with White MTW (WMTW). For
example, although HIV prevalence is elevated among MTW compared to the
general population, rates of new HIV infections among BMTW are 6.0 times
higher than rates among WMTW [2]. It is estimated that 61% of BMTW could be living with HIV by the time they reach age 40 [3].
Pre-exposure prophylaxis (PrEP), or the use of antiretrovirals such as Truvada®, to prevent HIV transmission among HIV negative persons at-risk for HIV is a highly effective option for HIV prevention [4, 5].
Although PrEP for HIV prevention was approved by the US FDA in 2012,
uptake of PrEP among individuals in-need has been limited [6–8].
In order for PrEP to have a population-level impact on incident HIV
infections, scale-up efforts must be prioritized and barriers to
implementation need to be addressed.
Broader implementation of PrEP for MTW could potentially result in a substantial decrease in incident HIV infections [9].
Multiple factors, however, have impeded access to and interest in
taking PrEP among MTW. Main barriers to use include a lack of
wide-spread messaging to promote PrEP in communities of elevated HIV
prevalence, costs associated concerns among individuals with no/limited
insurance, lack of prescribing providers [10], concerns regarding side-effects and long-term use, and sociocultural barriers to use [11], such as experiences of stigma [12, 13] and other negative beliefs about its use [14].
There
is increasing concern for the latter barrier, i.e., sociocultural
barriers to PrEP interest and use. Popular press reports regarding PrEP
have described individuals using PrEP as “Truvada Whores”—a disparaging
term that associates promiscuity with use of PrEP [13, 15]. These commentaries have generated considerable discussion on social media [16],
yet little empirical research has assessed what influence these
sociocultural barriers have had on individuals’ interest in PrEP. These
potential barriers to PrEP interest and use are not well-understood as
this topic is a novel area of research focus. In implementation
research, understanding how communities respond to prevention
strategies, either by adopting or rejecting them, is critical, but we
have very limited information on this topic with respect to PrEP.
Based
on what is known from informal reports and empirical research on how
PrEP has been embraced by communities, stigma related to PrEP uptake
appears to be an important sociocultural barrier to PrEP interest [13].
Briefly, stigma is a social construction where social devaluation
occurs through a process of labeling, stereotyping, separation, status
loss, and discrimination [17].
This process serves as a way to maintain social power structures by
subordinating those whose possess devalued characteristics and elevating
those who do not. In the case of PrEP, the emergence of negative
stereotyping—an important component of stigma—towards individuals who
use PrEP deserves further attention and understanding [18].
It
is known that the negative labeling of groups (in this case those who
use PrEP) can dissuade interest in being part of such group. For
example, simply using PrEP implies concern for risk of HIV transmission,
which, in turn, may imply engagement in sexual risk taking behavior.
Engagement in sexual risk taking has a long-standing history of
violating perceived social mores. Further, stigma by association is
also known to occur when an individual experiences stigma as a result
of being connected to a stigmatized person or group [17].
Negative interpersonal associations have the potential to affect how
individuals are perceived. In the case of PrEP, individuals may be
concerned about using an antiretroviral for HIV prevention if they
associate PrEP use with persons living with HIV—a highly stigmatized
group. These societal processes have stymied HIV prevention and
treatment efforts since the beginning of the epidemic [18, 19] and has the potential to inhibit PrEP implementation.
Along similar lines, conspiracy related beliefs about biomedical approaches to HIV prevention [20–22]
are also likely to affect PrEP implementation, but research in this
area has yet to be conducted. Conspiracy beliefs are typically thought
to imply that organizations or individuals in power furtively manipulate
events in a self-serving manner. Conspiracy beliefs in HIV treatment
have been attributed to a historical legacy of mistreatment of race
minority populations by medical establishments [23].
For example, it is well-documented that conspiracy beliefs about
biomedical strategies—primarily antiretroviral use—for HIV treatment are
prevalent and related to poor HIV-related health outcomes,
particularly, among HIV positive, race-minority individuals [24].
Given the existence of these beliefs in HIV treatment efforts, it is
probable that these beliefs would affect PrEP interest as well.